• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

    222.08 -4.58 (-2.02%)
    Official Closing Price Updated: 4:15 PM EDT, Apr 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Ascendis Pharma A/S - Ordinary Share

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
    In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL... 
    Via MarketMinute
    Topics Economy
    News headline image
    Agriculture Stock Up 53% Draws $12 Million Bet. Here's What Long-Term Investors Should Know ↗
    This agribusiness firm delivers grain, renewables, and plant nutrient solutions to commercial and industrial clients worldwide. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Ascendis (ASND) Q4 2025 Earnings Call Transcript ↗
    Ascendis (ASND) Q4 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    Ascendis Pharma (NASDAQ:ASND) Shares Drop After Q4 Earnings Miss on Wider-Than-Expected Loss ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Praxis Stock Surges 320% as One Biotech Investor's Buy Pushes Stake to Nearly $600 Million ↗
    Praxis Precision Medicines targets neurological and psychiatric disorders with a pipeline of precision therapies for CNS conditions. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Celcuity Stock Soars 700% in a Year as One Investor's $17 Million Buy Helps Create Top Two Position ↗
    Celcuity develops targeted cancer therapies and diagnostic platforms, with a focus on advancing precision medicine in oncology. 
    Via The Motley Fool
    News headline image
    Apogee Shares Up Nearly 100% in 12 Months, and This $62 Million Buy Signals Ongoing Conviction ↗
    Apogee Therapeutics develops biologic therapies targeting dermatology and respiratory conditions, with lead candidates in clinical trials. 
    Via The Motley Fool
    Topics Regulatory Compliance
    ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Minervini Trend Template with High Growth Momentum ↗
    Via Chartmill
    News headline image
    Earnings Scheduled For November 12, 2025 ↗
     
    Via Benzinga
    News headline image
    A Look Ahead: Ascendis Pharma's Earnings Forecast ↗
     
    Via Benzinga
    News headline image
    $80 Million Arcellx Sale Follows Steep Stock Drop as Rival Drug Emerges ↗
    Arcellx develops next-generation cell therapies targeting multiple myeloma and other hematologic cancers in the biotechnology sector. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Ascendis Pharma (ASND) Q4 2025 Earnings Transcript ↗
    Ascendis Pharma (ASND) Q4 2025 Earnings Transcript 
    Via The Motley Fool
    News headline image
    Ascendis Pharma (NASDAQ:ASND) Passes Minervini's Trend Template and High Growth Momentum Scan ↗
    Ascendis Pharma (ASND) meets Mark Minervini's strict criteria, showing a powerful technical uptrend paired with explosive revenue growth over 269%. 
    Via Chartmill
    News headline image
    Why Dyne Therapeutics Stock Was Crushing it This Week ↗
    The company has solid potential with its development of drugs targeting muscle disorders. 
    Via The Motley Fool
    Topics Artificial Intelligence
    News headline image
    How Do Investors Really Feel About Ascendis Pharma? ↗
     
    Via Benzinga
    News headline image
    Earnings Scheduled For August 7, 2025 ↗
     
    Via Benzinga
    News headline image
    European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility
    European American Depositary Receipts (ADRs) have recently experienced a period of significant fluctuation, reflecting a broader climate of market volatility that has ripple across global financial... 
    Via MarketMinute
    Topics Artificial Intelligence Economy Supply Chain
    News headline image
    Ascendis (ASND) Q3 2025 Earnings Call Transcript ↗
    Ascendis (ASND) Q3 2025 Earnings Call Transcript 
    Via The Motley Fool
    Topics Earnings
    News headline image
    Ascendis Pharma Likely To Report Narrower Q3 Loss; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call ↗
     
    Via Benzinga
    News headline image
    Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years ↗
     
    Via Benzinga
    News headline image
    Looking Into Ascendis Pharma AS's Recent Short Interest ↗
     
    Via Benzinga
    News headline image
    Ascendis Pharma A/S - ADR (NASDAQ:ASND) Shows Strong Growth Momentum in Technical and Fundamental Analysis ↗
    Ascendis Pharma (ASND) is a high-growth stock with strong technical uptrends and impressive fundamentals, including surging revenue and earnings momentum. 
    Via Chartmill
    News headline image
    What Does the Market Think About Ascendis Pharma AS? ↗
    Ascendis Pharma AS's (NYSE: ASND) short interest as a percent of float has fallen 14.63% since its last report. According to exchange reported data, there are now 2.29 million shares sold short, which... 
    Via Benzinga
    News headline image
    $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today ↗
    Ascendis Pharma (NASDAQ: ASND) has outperformed the market over the past 10 years by 13.64% on an annualized basis producing an average annual return of 26.77%. Currently, Ascendis Pharma has a market... 
    Via Benzinga
    News headline image
    PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment ↗
    BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study. 
    Via Benzinga
    News headline image
    $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth This Much Today ↗
     
    Via Benzinga
    News headline image
    Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today ↗
     
    Via Benzinga
    News headline image
    ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) Combines Technical Strength and High-Growth Momentum ↗
    Ascendis Pharma (ASND) excels in both technical & fundamental momentum, meeting Minervini's Trend Template criteria for high-growth stocks poised for potential outperformance. 
    Via Chartmill
    News headline image
    If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗
     
    Via Benzinga
    News headline image
    Ascendis (ASND) Q2 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.